Accessibility Menu
Matinas BioPharma Stock Quote

Matinas BioPharma (NYSEMKT: MTNB)

$1.53
(-7.2%)
-0.12
Price as of October 22, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$1.53
Daily Change
(-7.2%) $0.12
Day's Range
$1.53 - $1.64
Previous Close
$1.53
Open
$1.64
Beta
1.22
Volume
20,889
Average Volume
475,666
Market Cap
7.8M
Market Cap / Employee
$1.53M
52wk Range
$0.47 - $3.53
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$3.86
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Matinas BioPharma Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
MTNB-58.82%-96.58%-49.08%-98%
S&P+14.5%+93.32%+14.09%+239%

Matinas BioPharma Company Info

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.12M48.5%
Market Cap$4.53M-86.8%
Market Cap / Employee$0.65M0.0%
Employees7-78.1%
Net Income-$5.25M8.3%
EBITDA-$1.71M69.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$6.58M54.1%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.71M-32.5%
Short Term Debt$0.82M15.4%

Ratios

Q2 2025YOY Change
Return On Assets-109.58%-31.1%
Return On Invested Capital-96.00%-40.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$2.02M34.9%
Operating Free Cash Flow-$2.02M34.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.930.160.170.72-69.47%
Price to Sales42.86-
Price to Tangible Book Value1.200.230.231.13-66.53%
Enterprise Value to EBITDA-2.430.490.89-0.28-94.44%
Return on Equity-108.6%-180.7%-192.8%-146.5%50.08%
Total Debt$3.07M$2.89M$2.71M$2.53M-21.94%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.